In patients with atrial fibrillation who had a drug-eluting stent implanted at least 1 year prior, oral anticoagulation alone was noninferior to oral anticoagulation plus clopidogrel, researchers ...
A slew of National Institutes of Health grant terminations in the spring left affected Northwestern researchers with few ...
The Qatar Precision Health Institute (QPHI) is setting its sights on a bold transformation to make precision health part of ...
Opinion
13dOpinion
Amarin Issues Statement Supporting FDA's Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit
We applaud the FDA's decision to revise the labeling of fenofibrates (fibrates). The updated labeling now includes a clear statement on the lack of cardiovascular (CV) benefit, relevant safety data, ...
DES, adding clopidogrel in the chronic phase of coronary disease had no ischemic benefit and increased bleeding.
Novo Nordisk said on Thursday its experimental obesity drug CagriSema significantly reduced blood pressure in a late-stage ...
Somehow, it’s becoming even harder to get a GLP-1.
The results of two large-scale studies demonstrate that sodium-glucose co-transporter 2 (SGLT2) inhibitors significantly ...
After percutaneous coronary intervention (PCI), dual antiplatelet therapy (DAPT) is recommended for 6 months in stable coronary artery disease1,2 and 12 months in acute coronary syndromes.3,4 Over the ...
If approved, it would be the first major new drug treatment for Parkinson’s in half a century. Richard Mailman, a University ...
Vadodara: Alembic Pharmaceuticals Limited has announced that the company has received final approval from the US Food & Drug ...
Verywell Health on MSN
New Menopause Drug Lynkuet Could Ease Hot Flashes and Night Sweats
The FDA approved Lynkuet, a new nonhormonal menopause drug that reduces moderate to severe hot flashes and night sweats.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback